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Background: Limited data are available on the efficacy of β-blocker therapy for secondary prevention in patients with ST segment elevation 
myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI).
methods: Between November 2005 and September 2010, 20344 patients were enrolled in a nationwide, prospective, multi-center registry series 
for MI in Korea. Among these, we studied STEMI patients undergoing primary PCI who were discharged alive (n=8510). We classified patients into the 
β-blocker group (n=6873) and no-β-blocker group (n=1637) according to the use of β-blockers at discharge. Propensity-score matching analysis 
was also performed in 1371 patient pairs (2742 patients from the β-blocker group and 1371 patients from the no-β-blocker group). The primary 
outcome was all-cause death.
results: The median follow-up duration was 342 (interquartile range: 58 to 393) days. All-cause death occurred in 115 patients (1.7%) of the 
β-blocker group versus 49 patients (3.0%) of the no-β-blocker group (P < 0.001). After 2:1 propensity-score matching, β-blocker therapy was 
associated with a lower incidence of all-cause death (2.3% vs. 3.2%, adjusted hazard ratio 0.46, 95% confidence interval 0.25-0.84, P = 0.01). The 
benefit of β-blocker therapy in terms of all-cause death was consistent across various subgroups including patients with relatively low-risk profiles 
such as ejection fraction >40% or single vessel disease.
conclusions: Beta-blocker therapy at discharge was associated with improved survival in STEMI patients treated with primary PCI. Our results 
support the current ACC/AHA guidelines which recommend long-term β-blocker therapy in all patients with STEMI regardless of reperfusion therapy 
or risk profile.
